FRED HUTCHINSON CANCER CENTER

• LEIDOS BIOMEDICAL RESEARCH INC

  UEI HV8BH9BPG8Y9

  $10.9M

  Subcontractor to this prime · 2 sub-awards · latest Dec 1, 2025

  • National Institutes of Health
  • “IMPLEMENT, OPERATIONALIZE, AND MAINTAIN INFRASTRUCTURE TO SUPPORT MDNET MYELOMATCH ASSAYS AND ANALYSES; CYTOGENETIC ANALYSIS OF MDNET MYELOMATCH SPECIMENS; AND NCI MYELOID ASSAY (GENEXUS MYELOID NGS) ANALYSIS OF MDNET MYELOMATCH SPECIMENS.”
  • “THE SCOPE OF THIS WORK IS TO ADAPT THE IO-MASTER (IO-1, IO-2, AND IO-3) AND IO-4 ASSAYS FOR PARALLEL REACTION MONITORING. THE WORK SHALL INCLUDE CELL LINE AND PEPTIDE TESTING, DESIGN AND PRELIMINARY OPTIMIZATION OF PRM ASSAYS FOR CELL LINES, CLINICAL SAMPLE PREPARATION, OPTIMIZATION OF PRM ASSAYS FOR CLINICAL SAMPLES, AND VALIDATING THE PRM ASSAYS. UPDATES WILL BE PROVIDED TO THE LEIDOS BIOMEDICAL RESEARCH, INC. (LEIDOS BIOMED) TECHNICAL PROJECT MANAGER (TPM) AT MONTHLY TELECONFERENCES TO ENSURE THE WORK IS ON SCHEDULE AND MEETS CPTAC QUALITY STANDARDS. SEE CPTAC DCC WEBSITE FOR CPTAC STANDARD DETAILS: HTTPS://CPTAC-DATA-PORTAL.GEORGETOWN.EDU/CPTAC/STUDY/DISCLAIMER.”
• TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE

  UEI GM1XX56LEP58

  $1.5M

  Subcontractor to this prime · 4 sub-awards · latest May 20, 2026

  • National Institutes of Health
  • “BLOOM LAB THE BLOOM LAB WILL PERFORM EXPERIMENTAL AND COMPUTATIONAL WORK TO CHARACTERIZE INFLUENZA VIRUS EVOLUTION. IN PROJECT 3, THEY WILL USE MUTATIONAL ANTIGENIC PROFILING TO EXPERIMENTALLY MAP THE EFFECTS OF VIRAL MUTATIONS ON IMMUNE RECOGNITION. BEDFORD LAB THE BEDFORD LAB AT THE FRED HUTCH WILL BE RESPONSIBLE FOR IMPLEMENTATION OF PROJECT 3, AIM 2 (PREDICT AND VISUALIZE WHICH CIRCULATING CLADES OF INFLUENZA WILL DOMINATE USING PHYLOGENETIC ANALYSES, AGE-STRUCTURED SEROLOGY, MUTATIONAL ANTIGENIC PROFILING, AND VACCINATION COVERAGE). FOR THIS, THE BEDFORD LAB WILL DEVELOP AND IMPLEMENT A PREDICTIVE MODEL THAT INCORPORATES DATA GENERATED BY THE BLOOM LAB FOR PROJECT 3, AIM 1 AS WELL AS OTHER SEROLOGICAL DATA GENERATED BY THE CENTER. THE BEDFORD LAB WILL INTEGRATE THIS SEROLOGICAL DATA WITH PUBLICLY AVAILABLE INFLUENZA GENETIC SEQUENCE DATA. THIS MODEL WILL ESTIMATE THE EVOLUTIONARY TRAJECTORY OF THE INFLUENZA VIRUS POPULATION.”
  • “3. STATEMENT OF WORK 1. SCOPE: THE UNIVERSITY OF PENNSYLVANIA CENTER OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE (PENN-CEIRR) BRINGS TOGETHER RENOWNED RESEARCHERS AND CUTTING-EDGE TECHNOLOGIES TO DISCOVER NEW INFORMATION AND TOOLS NEEDED TO DECREASE THE MORTALITY AND MORBIDITY ASSOCIATED WITH INFLUENZA VIRUSES AND OTHER PATHOGENS. 2. TECHNICAL REQUIREMENTS. INDEPENDENTLY, AND NOT AS AN AGENT OF THE GOVERNMENT, THE CONTRACTOR SHALL FURNISH ALL NECESSARY SERVICES, QUALIFIED PROFESSIONAL, TECHNICAL, AND ADMINISTRATIVE PERSONNEL, MATERIAL, EQUIPMENT AND FACILITIES, NOT OTHERWISE PROVIDED BY THE GOVERNMENT UNDER THE TERMS OF THIS CONTRACT, AS NEEDED TO PERFORM THE TASKS SET FORTH BELOW. SPECIFICALLY, THE CONTRACTOR SHALL:”
  • “3. STATEMENT OF WORK 1. SCOPE: THE UNIVERSITY OF PENNSYLVANIA CENTER OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE (PENN-CEIRR) BRINGS TOGETHER RENOWNED RESEARCHERS AND CUTTING-EDGE TECHNOLOGIES TO DISCOVER NEW INFORMATION AND TOOLS NEEDED TO DECREASE THE MORTALITY AND MORBIDITY ASSOCIATED WITH INFLUENZA VIRUSES AND OTHER PATHOGENS. 2. TECHNICAL REQUIREMENTS. INDEPENDENTLY, AND NOT AS AN AGENT OF THE GOVERNMENT, THE CONTRACTOR SHALL FURNISH ALL NECESSARY SERVICES, QUALIFIED PROFESSIONAL, TECHNICAL, AND ADMINISTRATIVE PERSONNEL, MATERIAL, EQUIPMENT AND FACILITIES, NOT OTHERWISE PROVIDED BY THE GOVERNMENT UNDER THE TERMS OF THIS CONTRACT, AS NEEDED TO PERFORM THE TASKS SET FORTH BELOW. SPECIFICALLY, THE CONTRACTOR SHALL:”
• SEATTLE CHILDREN'S HOSPITAL

  UEI SZ32VTCXM799

  $967.7K

  Subcontractor to this prime · 3 sub-awards · latest Nov 14, 2025

  • National Institutes of Health
  • “IN YEAR 7, THE EDLEFSEN GROUP AT FRED HUTCHINSON CANCER CENTER (FRED HUTCH) WILL PROVIDE DATA QUALITY ASSURANCE PROCESSES AND ENSURE THE TIMELINESS AND ACCURACY OF STATISTICAL ANALYSES AND THE EFFECTIVE COMMUNICATION OF RESULTS. FRED HUTCH WILL DEVELOP REPRODUCIBLE RESEARCH ANALYSIS SOFTWARE AND NOVEL ANALYTICAL METHODS. IN ADDITION, FRED HUTCH WILL CONTRIBUTE TO THE DESIGN AND PROPER STATISTICAL CONDUCT OF ALL AIMS, AND ASSOCIATED DATA. DR. EDLEFSEN WILL COLLABORATE WITH AN INDEPENDENT CONTRACTOR BASED IN GDANSK, POLAND, TO PROVIDE BIOINFORMATICS EXPERTISE ON THE PROJECT. FRED HUTCH IS CONDUCTING THESE ACTIVITIES ON AN ONGOING BASIS AND CONDUCTING ACTIVITIES MEETING THESE DESCRIPTIONS IN ALL YEARS OF THE CONTRACT.”
  • “THIS STATEMENT OF WORK (SOW) OUTLINES THE ACTIVITIES THAT FRED HUTCHINSON CANCER CENTER (FHCC EDLEFSEN) WILL BE PERFORMING. NOTE THAT THE TASK NUMBERS BELOW REFLECT THE NUMBERING OF THE OVERALL ACTIVITIES IN THE PRIME CONTRACT. ALTHOUGH THIS SOW DETAILS THE COMPLETE SUITE OF PROPOSED WORK, THE TASKS ASSOCIATED WITH THIS CONTRACT ITERATION ARE LIMITED TO THE SPECIFIC ACTIVITIES OUTLINED BELOW, DELIVERABLES FOR THIS CONTRACT PERIOD ARE HIGHLIGHTED. YEAR 6 (BASE) €€Œ EDLEFSEN IN YEAR 6, THE EDLEFSEN GROUP AT FRED HUTCHINSON CANCER CENTER (FRED HUTCH) WILL PROVIDE DATA QUALITY ASSURANCE PROCESSES AND ENSURE THE TIMELINESS AND ACCURACY OF STATISTICAL ANALYSES AND THE EFFECTIVE COMMUNICATION OF RESULTS. FRED HUTCH WILL DEVELOP REPRODUCIBLE RESEARCH ANALYSIS SOFTWARE AND NOVEL ANALYTICAL METHODS. IN ADDITION, FRED HUTCH WILL CONTRIBUTE TO THE DESIGN AND PROPER STATISTICAL CONDUCT OF ALL AIMS, AND ASSOCIATED DATA. DR. EDLEFSEN WILL COLLABORATE WITH AN INDEPENDENT CONTRACTOR BASED IN GDANSK, POLAND, TO PROVIDE BIOINFORMATICS EXPERTISE ON THE PROJECT. FRED HUTCH IS CONDUCTING THESE ACTIVITIES ON AN ONGOING BASIS AND CONDUCTING ACTIVITIES MEETING THESE DESCRIPTIONS IN ALL YEARS OF THE CONTRACT.”
  • “THIS STATEMENT OF WORK (SOW) OUTLINES THE ACTIVITIES THAT FRED HUTCHINSON CANCER CENTER (FHCC) WILL BE PERFORMING. NOTE THAT THE TASK NUMBERS BELOW REFLECT THE NUMBERING OF THE OVERALL ACTIVITIES IN THE PRIME CONTRACT. ALTHOUGH THIS SOW DETAILS THE COMPLETE SUITE OF PROPOSED WORK, THE TASKS ASSOCIATED WITH THIS CONTRACT ITERATION ARE LIMITED TO THE SPECIFIC ACTIVITIES OUTLINED BELOW, DELIVERABLES FOR THIS CONTRACT PERIOD ARE HIGHLIGHTED. THROUGH THE EXECUTION OF THIS CONTRACT, WE WILL EXAMINE BASIC INDUCTION OF INNATE AND ADAPTIVE IMMUNITY FROM VACCINATION, INCLUDING STUDIES THAT ADDRESS NONTUBERCULOUS MYCOBACTERIA (NTM) INTERFERENCE, RNA VACCINE DELIVERY, PRIME-BOOST REGIMENS (INCLUDING BCG PRE-EXPOSURE), TRANSCRIPTOMIC HOST SIGNATURES, SYSTEMS BIOLOGY AND DURABLE IMMUNE MEMORY FOR THE FURTHER ADVANCEMENT OF THE EFFORT TO DESIGN AND EVALUATE AN EFFICACIOUS VACCINE AGAINST MYCOBACTERIUM TUBERCULOSIS (M.TB) THE WORK UNDER THIS CONTRACT MAY INCLUDE THE POSSIBLE DISTRIBUTION OF DE-IDENTIFIED HUMAN SUBJECT PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC), SERUM, AND OTHER CLINICAL SAMPLES TO SCRI AND THE PHOENIX PARTNERS. NHP SAMPLES AND/OR DOWNSTREAM DATA MAY BE SHARED WITH THE PARTNERS ON THIS CONTRACT. OPTION 3 ACTIVITIES: EVALUATE OPTIMIZED M.TB VACCINE CANDIDATES FOR SAFETY, IMMUNOGENICITY AND EFFICACY IN THE NHP MODEL OF TB TASK 3.5 TRANSCRIPTOMIC ANALYSIS OF NHP SAMPLES. FHCC WILL EXECUTE GENE EXPRESSION PROFILING WITH RNASEQ/NANOSTRING ASSAYS ON NHP SAMPLES GENERATED IN OPTION 3 AT UKHSA. TRANSCRIPTOMIC ANALYSIS WILL BE FOCUSED ON IDENTIFYING A PERIPHERAL BLOOD SURROGATE ENDPOINT FOR THE M.TB ERDMAN ULDA CHALLENGE OUTCOMES. THE INITIAL UNBIASED RNA SEQUENCING APPROACH WILL USE WHOLE-BLOOD SAMPLES FROM PRE- AND POST-CHALLENGE TIME POINTS. SPECIFICALLY, WE WILL LOOK FOR TRANSCRIPTS THAT ARE CORRELATED WITH M.TB COLONY FORMING UNITS (CFU) AND M.TB QPCR ASSAYS FROM BRONCHOALVEOLAR LAVAGE (BAL), THE PRIMARY CHALLENGE OUTCOMES. IN ADDITION TO ABSOLUTE ABUNDANCE AT PO”
• ST JUDE CHILDREN'S RESEARCH HOSPITAL INC

  UEI JL4JHE9SDRR3

  $791.2K

  Subcontractor to this prime · 3 sub-awards · latest May 1, 2026

  • National Institutes of Health
  • “4.4.1 FRED HUTCH COMPREHENSIVE IMMUNOLOGICAL PROFILES OF INFLUENZA INFECTION SUSCEPTIBILITY (THOMAS) (MOD 29)”
  • “OPTION 16D: CURATING THE COVID CODEX FOR CORRELATES (THOMAS) (MOD 21)”
  • “4.4.1 COMPREHENSIVE IMMUNOLOGICAL PROFILES OF INFLUENZA INFECTION SUSCEPTIBILITY (THOMAS)”
• KAISER FOUNDATION HOSPITALS

  UEI P1RTMASB37B5

  $220K

  Subcontractor to this prime · 1 sub-award · latest Jan 16, 2026

  • Office of the Assistant Secretary for Financial Resources
  • “THE CISNET COLORECTAL CANCER WORKING GROUP SHALL CONDUCT A DECISION ANALYSIS USING A COLLABORATIVE MODELING APPROACH TO SUPPORT THE USPSTF SCREENING FOR COLORECTAL CANCER RECOMMENDATION STATEMENT. AS PART OF THIS WORK, A RESEARCH PLAN, DECISION ANALYSIS REPORT, AND MANUSCRIPT WILL BE PRODUCED.”

• UNIVERSITY OF WASHINGTON

  UEI NFJ3CMQ4B418 · not in the directory yet

  $275.9K

  Subcontracted by this company · 1 sub-award · latest Sep 9, 2026

  • National Institutes of Health
  • “REINER 4/1-5/31/26”
• UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

  UEI D3LHU66KBLD5

  $99.8K

  Subcontracted by this company · 1 sub-award · latest Apr 24, 2026

  • National Institutes of Health
  • “PER WHI POLICY, EVENTS ELIGIBLE FOR INVESTIGATION FOR HEART FAILURE WILL BE IDENTIFIED BY WHI STAFF. MEDICAL RECORDS WILL BE OBTAINED FOR ELIGIBLE HOSPITALIZATION AND SENT TO WHI REGIONAL CENTERS FOR INITIAL VERIFICATION AND DETERMINATION OF COMPLETENESS. ELECTRONIC COPIES OF ASSEMBLED MEDICAL RECORDS ARE SENT TO THE COORDINATING CENTER AT THE UNIVERSITY OF NORTH CAROLINA. THE UNC COORDINATING CENTER RECEIVES LOGS AND VERIFIES RECEIPT OF MEDICAL RECORDS. UNC COORDINATING CENTER WILL USE A WEB-BASED DATA ENTRY SYSTEM FOR THE WHI HEART FAILURE DATA ABSTRACTION AND FOR CAPTURING THE PHYSICIAN ADJUDICATOR CLASSIFICATION. TRAINED MEDICAL RECORDS ABSTRACTORS WILL REVIEW RECORDS AND COMPLETE HEART FAILURE DATA COLLECTION TOOL. NUMBER OF HEART FAILURE ELIGIBLE CASES ESTIMATED TO BE IDENTIFIED BY WHI AND SENT TO THE UNC COORDINATING CENTER FOR ABSTRACTION AND CLASSIFICATION: YEAR 6 = 250 YEAR 7 = 250”
• EDTAN, LLC

  UEI RJWFATCHHTD7 · not in the directory yet

  $44.9K

  Subcontracted by this company · 1 sub-award · latest Sep 23, 2026

  • National Institutes of Health
  • “WHI NEWSLETTERS PRINTING AND S”
• PROVANTAGE LLC

  UEI TB1FS3UMCPG3

  $25.1K

  Subcontracted by this company · 1 sub-award · latest Aug 5, 2026

  • National Institutes of Health
  • “PROVANTAGE HARD DRIVES: WD261K”

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.